Cryo-Cell International, Inc. (CCEL) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Cryo-Cell International, Inc. (CCEL) Healthcare & Pipeline Overview

Cryo-Cell International focuses on the niche market of cellular processing and cryogenic storage, providing umbilical cord blood and tissue preservation services. Their PrepaCyte CB processing system and direct-to-consumer marketing strategy position them as a key player in the family cord blood banking sector, serving a global clientele.

What Is the Investment Thesis for CCEL?

Cryo-Cell International operates in the niche but growing market of cord blood and tissue preservation. The company's high gross margin of 77.5% indicates strong pricing power and efficient operations. A dividend yield of 4.37% may attract income-focused investors. The company's focus on direct-to-consumer marketing and partnerships with healthcare professionals provides a competitive edge in acquiring new clients. However, the company's negative profit margin of -8.5% raises concerns about profitability and cost management. The relatively small market capitalization of $33.9M may limit liquidity and increase volatility. Future growth depends on increasing awareness and acceptance of cord blood and tissue preservation, as well as successful expansion into new markets and therapeutic applications. Investors should closely monitor the company's ability to improve profitability and manage costs effectively.

Based on FMP financials and quantitative analysis

CCEL Key Highlights

Market capitalization of $33.9M indicates a small-cap company with potential for growth but also higher volatility.

• Gross margin of 77.5% reflects strong pricing power and efficient cost management in its core services.
• Dividend yield of 4.37% provides an attractive income stream for investors, potentially offsetting some risk.
• Profit margin of -8.5% signals challenges in achieving profitability and requires close monitoring of cost control measures.
• Beta of 0.63 suggests lower volatility compared to the overall market, potentially making it a more stable investment.

Who Are CCEL's Competitors?

CCEL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CCEL's Key Strengths?

Established presence in the niche market of cord blood and tissue preservation.

• Proprietary PrepaCyte CB processing system.
• Direct-to-consumer marketing strategy.
• High gross margin of 77.5%.

What Are CCEL's Weaknesses?

Negative profit margin of -8.5%.

• Small market capitalization may limit liquidity.
• Dependence on consumer awareness and acceptance of cord blood banking.
• Limited diversification of revenue streams.

What Could Drive CCEL Stock Higher?

CCEL catalyst: Potential regulatory approvals for new stem cell therapies could increase demand for cord blood and tissue preservation.

• Increasing awareness of the therapeutic applications of stem cells through research and clinical trials.
• Strategic partnerships with healthcare providers to expand customer reach and streamline operations.

What Are the Key Risks for CCEL?

Financial-distress signal — its Altman Z-Score of -0.24 sits in the distress zone (elevated bankruptcy risk).

• Intense competition from other cord blood banks may put pressure on pricing and market share.
• Regulatory changes and evolving standards for cord blood banking could increase compliance costs.
• Ethical concerns and public perception of stem cell research may impact consumer demand.
• Economic downturns may reduce consumer spending on non-essential services like cord blood banking.

What Are the Growth Opportunities for CCEL?

• Expansion into New Therapeutic Applications: The increasing research and development in regenerative medicine presents an opportunity for Cryo-Cell International to expand the therapeutic applications of stored cord blood and tissue. As new clinical trials demonstrate the efficacy of stem cells in treating various diseases, the demand for cord blood and tissue preservation is likely to increase. Cryo-Cell can capitalize on this trend by actively promoting the potential benefits of stem cell therapy and partnering with research institutions to explore new applications.
• Geographic Expansion: Cryo-Cell International can pursue growth by expanding its services into new geographic markets. Emerging economies with growing healthcare awareness and increasing disposable incomes present attractive opportunities. By establishing partnerships with local healthcare providers and adapting its marketing strategies to suit regional preferences, Cryo-Cell can tap into new customer segments and increase its global market share. This expansion requires careful market research and strategic investments in infrastructure and marketing, but it has the potential to significantly boost revenue and profitability.
• Strategic Partnerships with Healthcare Providers: Strengthening partnerships with obstetricians, pediatricians, and other healthcare professionals can drive customer acquisition and increase brand awareness. By offering educational resources and incentives to healthcare providers, Cryo-Cell can encourage them to recommend its services to expectant parents. These partnerships can also facilitate the collection and processing of cord blood and tissue, streamlining the customer experience and improving operational efficiency. Building strong relationships with key influencers in the healthcare community is crucial for driving sustainable growth and maintaining a competitive edge.
• Development of New Processing and Storage Technologies: Investing in research and development to improve cord blood and tissue processing and storage technologies can enhance the quality and viability of stored stem cells. By developing innovative techniques that maximize stem cell recovery and minimize cell damage during cryopreservation, Cryo-Cell can differentiate itself from competitors and attract customers seeking the highest quality preservation services. These technological advancements can also lead to cost savings and improved operational efficiency, further enhancing profitability and competitiveness.
• Direct-to-Consumer Marketing and Education: Enhancing direct-to-consumer marketing efforts and educational campaigns can increase awareness of the benefits of cord blood and tissue preservation among expectant parents. By leveraging digital marketing channels, social media, and targeted advertising, Cryo-Cell can reach a wider audience and educate them about the potential therapeutic applications of stem cells. These campaigns can also address common misconceptions and concerns about cord blood banking, building trust and credibility among potential customers. Effective marketing and education are essential for driving customer acquisition and sustaining long-term growth in the competitive cord blood banking market.

What Are CCEL's Competitive Advantages?

• Established brand reputation and long-standing presence in the cord blood banking industry.
• Proprietary PrepaCyte CB processing system provides a technological advantage.
• Extensive network of healthcare professional partnerships for customer acquisition.
• Large storage capacity of approximately 500,000 cord blood and tissue stem cells.

What Does CCEL Do?

Cryo-Cell International, Inc., founded in 1989 and headquartered in Oldsmar, Florida, operates within the healthcare sector, specializing in cellular processing and cryogenic cellular storage. The company's core business revolves around the collection and preservation of umbilical cord blood stem cells for family use, offering expectant parents the option to store these cells for potential future medical needs. Cryo-Cell also provides cord tissue services, storing sections of the umbilical cord tissue, a source of mesenchymal stem cells. These cells are increasingly valuable in regenerative medicine, showing promise in treating conditions such as heart and kidney disease, ALS, wound healing, and autoimmune disorders. In addition to its storage services, Cryo-Cell International manufactures and sells the PrepaCyte CB processing system, a technology designed to process umbilical cord blood stem cells efficiently. The company has built a significant global presence, storing approximately 500,000 cord blood and cord tissue stem cells worldwide. Cryo-Cell markets its preservation services directly to expectant parents, utilizing a multi-channel approach that includes direct outreach and partnerships with obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other healthcare professionals. This targeted marketing strategy allows Cryo-Cell to effectively reach its core customer base and educate them about the potential benefits of cord blood and tissue preservation. Cryo-Cell's comprehensive service offerings and established market presence solidify its position as a key player in the family cord blood banking industry.

What Products and Services Does CCEL Offer?

• Collect and preserve umbilical cord blood stem cells for family use.
• Provide cord tissue services, storing sections of the umbilical cord tissue.
• Offer mesenchymal stem cells for potential use in regenerative medicine.
• Manufacture and sell the PrepaCyte CB processing system.
• Market cord blood stem cell preservation services directly to expectant parents.
• Distribute information through healthcare professionals like obstetricians and pediatricians.
• Store approximately 500,000 cord blood and cord tissue stem cells worldwide.

How Does CCEL Make Money?

• Generate revenue through the collection and cryogenic storage of umbilical cord blood and tissue stem cells.
• Sell the PrepaCyte CB processing system to other cord blood banks and research institutions.
• Market services directly to expectant parents through various channels.
• Partner with healthcare professionals to promote and facilitate cord blood and tissue collection.

What Industry Does CCEL Operate In?

Cryo-Cell International operates within the medical care facilities industry, a segment of the broader healthcare sector. The market for cord blood and tissue banking is driven by increasing awareness of the potential therapeutic applications of stem cells in regenerative medicine. The competitive landscape includes both private and public cord blood banks, as well as hospital-based programs. Cryo-Cell differentiates itself through its direct-to-consumer marketing approach and its PrepaCyte CB processing system. The industry is subject to regulatory oversight and evolving standards for cord blood banking practices.

Who Are CCEL's Key Customers?

• Expectant parents seeking to preserve their child's cord blood and tissue stem cells.
• Families interested in potential future medical applications of stem cells.
• Healthcare professionals, including obstetricians, pediatricians, and nurse-midwives.
• Research institutions and other cord blood banks using the PrepaCyte CB processing system.

How Cryo-Cell International, Inc. Is Valued

Cryo-Cell International, Inc. carries a market capitalization of $33.9M, placing it in the micro-cap category. Relative to its peer group, CCEL's quantitative score of 30/100 is below the peer average of 60/100.

Company Profile

Cryo-Cell International, Inc. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Oldsmar, US. The company is led by CEO David Portnoy. CCEL has traded publicly since 1994.

Return on equity for Cryo-Cell International, Inc. stands at 15.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -4.4%, showing how much profit it generates from its asset base. Its free cash flow yield is 19.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.62 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -10.4%, the inverse of the P/E and a quick read on earnings relative to price.

Cryo-Cell International, Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -0.24 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project Cryo-Cell International, Inc. revenue of about $30.0M for fiscal 2026, with EPS near $0.11.

CCEL Financials

CCEL Latest News

CCEL Analyst Consensus

CCEL MoonshotScore

What Investors Ask About Cryo-Cell International, Inc. (CCEL) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources